The Department of Health & Human Services’ Office of Inspector General (HHS OIG) and U.S. Department of Justice (DOJ) have published important guidance and recommendations for pharmaceutical companies to develop and implement effective compliance programs. Both HHS OIG and DOJ have made it absolutely clear that robust, multifaceted compliance programs are a must for pharmaceutical companies.
Please see full publication below for more information.
